Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SAN DIEGO, March 21, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present a corporate update at the 17th Annual Needham Healthcare Conference at 2:30 pm EDT on Wednesday, March 28, 2018, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Patricia Bitar | Andrew McDonald |
| Chief Financial Officer | LifeSci Advisors LLC |
| (858) 550‐0780 ext. 223 | 646-597-6987 |
| [email protected] | [email protected] |
